SARS-CoV-2 vaccination efficacy and B-cell depletion therapy in systemic lupus erythematosus: Description of a case

Abstract

Get full access to this article

View all access options for this article.

References

Poland

Ovsyannikova

Kennedy

RB.

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020; 396: 1595–1606.

Iaccarino

Bartoloni

Carli

, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the italian multicentre registry. ClinExpRheumatol 2015; 33: 449–456.

McLaughlin

Grillo-López

Link

, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

Furer

Rondaan

Heijstek

, et al. 2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020; 79: 39–52.

Khayat-Khoei

Conway

Rubinson

, et al. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. J Neurol 2021; 27: 1–3.

Spiera

Jinich

Jannat-Khah

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. Epub ahead of print 11 May 2021.